advanced systemic mastocytosis
Haematology · 2025–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| midostaurin Treatment of adult patients with advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an… | Mar 2025 | Recommended with restriction | input received Leukaemia Foundation |
Who spoke
Leukaemia Foundation
What the PBS pays
$11M in government benefit over 2024–25, across 730 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| midostaurin | $10.7M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.